ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2013

Abstract Number: 2573

The Role Of STAT-3 In The Development Of Pulmonary and Dermal Fibrosis

Mesias Pedroza1, Sarah To1, Anuh T. George1, David J. Tweardy2 and Sandeep K. Agarwal1, 1Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, 2Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2013

Keywords: cytokines, Lung Disease, signal transduction, skin and systemic sclerosis

Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Fibrosis is the accumulation of excessive extra-cellular matrix in tissues, leading to tissue damage.  In systemic sclerosis, the trigger is postulated to be an autoimmune response that leads to tissue injury, production of growth factors, pro-inflammatory and profibrotic cytokines, and accumulation of myofibroblasts.  Two potential sources of myofibroblasts are the differentiation of local fibroblasts and the process of epithelial-to-mesenchymal transition (EMT).  IL-6 is a proinflammatory and profibrotic cytokine that is increasingly recognized as an important mediator of fibrosis and may contribute to the accumulation of myofibroblasts.  After engaging its receptor, IL-6 signals through the STAT-3.  STAT-3 has been shown to be elevated in skin and pulmonary fibrosis. The extent to which STAT-3 is involved in the development of fibrosis and the mechanisms by which it leads to fibrosis are not known. We hypothesizes that STAT-3 signaling contributes to the development of tissue fibrosis in the lung and skin in part through the modulation of EMT.  

Methods: Fibrotic tissue from systemic sclerosis patients, idiopathic pulmonary fibrosis patients, and mouse models of lung and skin fibrosis was processed for phosphor-STAT-3 staining by immunohistology.  To determine if STAT-3 signaling contributes to the development of fibrosis, C-188-9, a novel small molecule STAT-3 inhibitor, was administered to C57/Bl-6 mice in both the intraperitoneal (IP) bleomycin mouse model of lung fibrosis and the subcutaneous (SC) bleomycin mouse model of skin fibrosis.  To determine the role of STAT-3 in EMT and myofibroblast differentiation, C-188-9 was used in tissue culture experiments with alveolar epithelial cells (AEC; MLE-12 and primary AEC) and murine lung fibroblasts.

Results: Phospho-STAT-3 expression was increased in fibrotic tissue from systemic sclerosis patients, idiopathic pulmonary fibrosis patients, and mouse models of lung and skin fibrosis.  STAT-3 inhibition by C-188-9 decreased fibrotic endpoints (collagen deposition by Sircol, expression of alpha-smooth muscle actin (SMA), and improved arterial oxygen saturation) in the IP bleomycin pulmonary fibrosis model.  C-188-9 also decreased the development of dermal fibrosis in the SC bleomycin model as assessed by decreased dermal thickness, a reduction of alpha-SMA accumulation, and decreased collagen deposition. In vitro studies show that TGF-beta or IL-6 trans-signaling (IL-6/sIL-6R-alpha) were able to induce 1) EMT on primary AEC and MLE-12 cell line and 2) myofibroblast differentiation from fibroblasts. C-188-9 prevented TGF-beta and IL-6/sIL-6R-alpha induced EMT assessed by Col1a, alpha-SMA, Twist, and Snail mRNA levels and reduced myofibroblast differentiation as assessed by Col1a and alpha-SMA mRNA levels.

Conclusion: These findings demonstrate that STAT-3 contributes to the development of tissue fibrosis in the skin and the lung and plays a role in the development of myofibroblasts in vitro.  Furthermore, these data suggest that STAT-3 may be a therapeutic target in the treatment of dermal and pulmonary fibrosis.


Disclosure:

M. Pedroza,
None;

S. To,
None;

A. T. George,
None;

D. J. Tweardy,

StemMed LtdP,

1;

S. K. Agarwal,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-role-of-stat-3-in-the-development-of-pulmonary-and-dermal-fibrosis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology